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Introduction
• Severe and prolonged hypoglycemia can be life 
threatening and may be associated with 
increased mortality in patients with diabetes. 
• We highlight a case of refractory hypoglycemia 
in an elderly, diabetic patient with chronic 
kidney disease (CKD) despite treatment.
Case Report
• 76-year-old male with history of hypertension, 
paroxysmal atrial fibrillation, type 2 diabetes 
mellitus (T2DM), CKD Stage III, and 
paraproteinemia (MGUS) presented with 
dyspnea and generalized weakness. He was 
admitted for worsening renal failure, uremia, 
and anasarca.
• His renal function worsened from a baseline 
creatinine of 2.2 mg/dL to 4.12 mg/dL and 
subsequently developed recurrent episodes of 
hypoglycemia as low as 48 mg/dL despite
discontinuation of home medications (insulin 
glargine, glimepiride, and sitagliptin). HbA1C 
was 7%. 
• He was given ampules of D50. On day 2, 
patient had persistent  hypoglycemia, so a D10 
infusion was initiated.
Discussion
• Eighty-seven percent of sitagliptin (80% 
unchanged) is excreted through urine in patients 
with CKD.
• Both plasma concentrations of sitagliptin and its 
terminal half-life are increased by four-fold, thus 
potentiating the risk for hypoglycemia.
• Sitagliptin is well tolerated as monotherapy for 
patients with T2DM and CKD. However, when 
used in combination therapy in the setting of CKD 
the risk for refractory hypoglycemia increases.
Discussion Continued
• DPP-IV inhibitors are not dialyzable, so 
emergent hemodialysis is limited as a treatment 
option. 
• We believe our patient’s acute renal failure, 
superimposed on CKD and paraproteinemia, led 
to an unexpected increase in the concentration of 
sitagliptin in plasma. This increased level, in 
addition to impaired renal clearance, 
inadvertently resulted in refractory 
hypoglycemia. 
• Dialysis likely aided in the clearance of protein 
deposition in the kidneys which improved renal 
function, thus allowing sitagliptin to be cleared 
and his hypoglycemia to subsequently resolve.
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Conclusion
• Among U.S. adults 18 years of age and older with 
diabetes, 37.0% had CKD, and over half of those 
had moderate to severe CKD.
• Hospitalists should be aware of the potential for 
refractory hypoglycemia when sitagliptin is used in 
combination with other diabetic medications in the 
setting of AKI superimposed on CKD as it can 
threaten patient safety in the hospital environment.
Case Report Continued
• Day 3 – Hemodialysis was initiated for 
progressive renal failure/ anasarca, but he 
continued to have hypoglycemic episodes. On 
day 5, following his third dialysis session, his 
glucose levels began to normalize. 
• Over a 5-day period he required a total of 29 
ampules of D50 and 72 hours of a D10 drip.
• At discharge, his renal function returned to 
baseline and his T2DM regimen was adjusted 
to insulin glargine and lispro.
